These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 25842825)

  • 1. [Frequency of CHEK2 gene mutations in patients with breast cancer from the Republic of Bashkortostan].
    Mol Biol (Mosk); 2014; 48(1):55-61. PubMed ID: 25842825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of two mutations in the CHEK2 gene with breast cancer.
    Bogdanova N; Enssen-Dubrowinskaja N; Feshchenko S; Lazjuk GI; Rogov YI; Dammann O; Bremer M; Karstens JH; Sohn C; Dörk T
    Int J Cancer; 2005 Aug; 116(2):263-6. PubMed ID: 15810020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different CHEK2 germline mutations are associated with distinct immunophenotypic molecular subtypes of breast cancer.
    Domagala P; Wokolorczyk D; Cybulski C; Huzarski T; Lubinski J; Domagala W
    Breast Cancer Res Treat; 2012 Apr; 132(3):937-45. PubMed ID: 21701879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Germline CHEK2 Gene Mutations in Hereditary Breast Cancer Predisposition - Mutation Types and their Biological and Clinical Relevance.
    Kleiblová P; Stolařová L; Křížová K; Lhota F; Hojný J; Zemánková P; Havránek O; Vočka M; Černá M; Lhotová K; Borecká M; Janatová M; Soukupová J; Ševčík J; Zimovjanová M; Kotlas J; Panczak A; Veselá K; Červenková J; Schneiderová M; Burócziová M; Burdová K; Stránecký V; Foretová L; Macháčková E; Tavandzis S; Kmoch S; Macůrek L; Kleibl Z
    Klin Onkol; 2019; 32(Supplementum2):36-50. PubMed ID: 31409080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CHEK2-positive breast cancers in young Polish women.
    Cybulski C; Górski B; Huzarski T; Byrski T; Gronwald J; Debniak T; Wokolorczyk D; Jakubowska A; Kowalska E; Oszurek O; Narod SA; Lubinski J
    Clin Cancer Res; 2006 Aug; 12(16):4832-5. PubMed ID: 16914568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CHEK2 1100delC and Del5395bp mutations in BRCA-negative individuals from Serbian hereditary breast and ovarian cancer families.
    Krivokuca A; Dobricic J; Brankovic-Magic M
    J BUON; 2013; 18(3):594-600. PubMed ID: 24065469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of CHEK2 missense variant I157T on the risk of breast cancer in carriers of other CHEK2 or BRCA1 mutations.
    Cybulski C; Górski B; Huzarski T; Byrski T; Gronwald J; Debniak T; Wokolorczyk D; Jakubowska A; Serrano-Fernández P; Dork T; Narod SA; Lubinski J
    J Med Genet; 2009 Feb; 46(2):132-5. PubMed ID: 18930998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A deletion in CHEK2 of 5,395 bp predisposes to breast cancer in Poland.
    Cybulski C; Wokołorczyk D; Huzarski T; Byrski T; Gronwald J; Górski B; Debniak T; Masojć B; Jakubowska A; van de Wetering T; Narod SA; Lubiński J
    Breast Cancer Res Treat; 2007 Mar; 102(1):119-22. PubMed ID: 16897426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased Risk for Other Cancers in Addition to Breast Cancer for CHEK2*1100delC Heterozygotes Estimated From the Copenhagen General Population Study.
    Näslund-Koch C; Nordestgaard BG; Bojesen SE
    J Clin Oncol; 2016 Apr; 34(11):1208-16. PubMed ID: 26884562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing Cancer Risk Management between Females with Truncating
    Garmendia D; Weidner A; Venton L; Pal T
    Genes (Basel); 2024 Jul; 15(7):. PubMed ID: 39062660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CHEK2 1100delC, IVS2+1G>A and I157T mutations are not present in colorectal cancer cases from Turkish population.
    Bayram S; Topaktaş M; Akkız H; Bekar A; Akgöllü E
    Cancer Epidemiol; 2012 Oct; 36(5):453-7. PubMed ID: 22521562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient survival and tumor characteristics associated with CHEK2:p.I157T - findings from the Breast Cancer Association Consortium.
    Muranen TA; Blomqvist C; Dörk T; Jakubowska A; Heikkilä P; Fagerholm R; Greco D; Aittomäki K; Bojesen SE; Shah M; Dunning AM; Rhenius V; Hall P; Czene K; Brand JS; Darabi H; Chang-Claude J; Rudolph A; Nordestgaard BG; Couch FJ; Hart SN; Figueroa J; García-Closas M; Fasching PA; Beckmann MW; Li J; Liu J; Andrulis IL; Winqvist R; Pylkäs K; Mannermaa A; Kataja V; Lindblom A; Margolin S; Lubinski J; Dubrowinskaja N; Bolla MK; Dennis J; Michailidou K; Wang Q; Easton DF; Pharoah PD; Schmidt MK; Nevanlinna H
    Breast Cancer Res; 2016 Oct; 18(1):98. PubMed ID: 27716369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer.
    Cybulski C; Wokołorczyk D; Jakubowska A; Huzarski T; Byrski T; Gronwald J; Masojć B; Deebniak T; Górski B; Blecharz P; Narod SA; Lubiński J
    J Clin Oncol; 2011 Oct; 29(28):3747-52. PubMed ID: 21876083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CHEK2 mutations and the risk of papillary thyroid cancer.
    Siołek M; Cybulski C; Gąsior-Perczak D; Kowalik A; Kozak-Klonowska B; Kowalska A; Chłopek M; Kluźniak W; Wokołorczyk D; Pałyga I; Walczyk A; Lizis-Kolus K; Sun P; Lubiński J; Narod SA; Góźdż S
    Int J Cancer; 2015 Aug; 137(3):548-52. PubMed ID: 25583358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitivity to systemic therapy for metastatic breast cancer in CHEK2 1100delC mutation carriers.
    Kriege M; Jager A; Hollestelle A; Berns EM; Blom J; Meijer-van Gelder ME; Sieuwerts AM; van den Ouweland A; Collée JM; Kroep JR; Martens JW; Hooning MJ; Seynaeve C
    J Cancer Res Clin Oncol; 2015 Oct; 141(10):1879-87. PubMed ID: 25958056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Germline CHEK2 mutations in Jewish Ashkenazi women at high risk for breast cancer.
    Laitman Y; Kaufman B; Lahad EL; Papa MZ; Friedman E
    Isr Med Assoc J; 2007 Nov; 9(11):791-6. PubMed ID: 18085035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Significance of CHEK2 Mutation in Progression of Breast Cancer.
    Ansari N; Shahrabi S; Khosravi A; Shirzad R; Rezaeean H
    Lab Med; 2019 Jul; 50(3):e36-e41. PubMed ID: 31220302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival from breast cancer in patients with CHEK2 mutations.
    Huzarski T; Cybulski C; Wokolorczyk D; Jakubowska A; Byrski T; Gronwald J; Domagała P; Szwiec M; Godlewski D; Kilar E; Marczyk E; Siołek M; Wiśniowski R; Janiszewska H; Surdyka D; Sibilski R; Sun P; Lubiński J; Narod SA
    Breast Cancer Res Treat; 2014 Apr; 144(2):397-403. PubMed ID: 24557336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spectrum and frequency of CHEK2 variants in breast cancer affected and general population in the Baltic states region, initial results and literature review.
    Pavlovica K; Irmejs A; Noukas M; Palover M; Kals M; Tonisson N; Metspalu A; Gronwald J; Lubinski J; Murmane D; Kalnina A; Loza P; Maksimenko J; Trofimovics G; Subatniece S; Daneberga Z; Miklasevics E; Gardovskis J
    Eur J Med Genet; 2022 May; 65(5):104477. PubMed ID: 35314380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A risk of breast cancer in women - carriers of constitutional CHEK2 gene mutations, originating from the North - Central Poland.
    Bąk A; Janiszewska H; Junkiert-Czarnecka A; Heise M; Pilarska-Deltow M; Laskowski R; Pasińska M; Haus O
    Hered Cancer Clin Pract; 2014 Apr; 12(1):10. PubMed ID: 24713400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.